Comparison of Clinical Trials with Finasteride and Dutasteride

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.